|
|||||
|
|

Health and wellness products company USANA Health Sciences (NYSE:USNA) met Wall Street’s revenue expectations in Q4 CY2025, with sales up 5.9% year on year to $226.2 million. The company’s full-year revenue guidance of $962.5 million at the midpoint came in 0.7% above analysts’ estimates. Its non-GAAP profit of $0.60 per share was 46.3% above analysts’ consensus estimates.
Is now the time to buy USNA? Find out in our full research report (it’s free for active Edge members).
USANA’s fourth quarter results met Wall Street’s expectations on revenue and surpassed estimates for non-GAAP profit, yet the market responded negatively. Management attributed this to ongoing margin pressures and a continued shift in business mix, particularly the growing role of lower-margin brands like Rise Wellness and Hiya. CEO Kevin Guest, who resumed his leadership role, highlighted operational changes and a strategic pivot toward omnichannel distribution and scientific product innovation. He acknowledged headwinds, saying, “Our core business has faced year-over-year sales declines, but we are seeing encouraging signs of stabilization.”
Looking ahead, USANA’s guidance reflects optimism about its expanding omnichannel strategy and new product initiatives, especially for Hiya and Rise Wellness. Management emphasized the importance of technology upgrades and leveraging AI to personalize customer experiences. Guest outlined the company’s focus: “We have to play in [AI] and be as good at technology and utilizing AI as we are in Nutrition.” The leadership team also noted that execution in retail partnerships and international markets will be critical, as will disciplined cost management, to capture emerging growth opportunities and support long-term profitability.
USANA’s fourth quarter call emphasized a strategic evolution, with management focusing on omnichannel growth, operational discipline, and new product expansion as primary levers for future performance.
USANA’s outlook for the coming year centers on scaling new brands, broadening retail partnerships, and investing in technology to support growth, while managing margin headwinds.
In the coming quarters, our analysts will watch (1) the pace of retail distribution and international expansion for Hiya and Rise Wellness, (2) whether technology upgrades and AI initiatives translate into improved customer engagement and operational efficiency, and (3) the company’s ability to stabilize gross margins despite a shifting business mix. Sustained momentum in omnichannel partnerships will also be a key metric of success.
USANA currently trades at $18.99, down from $20.67 just before the earnings. Is the company at an inflection point that warrants a buy or sell? Find out in our full research report (it’s free).
The market’s up big this year - but there’s a catch. Just 4 stocks account for half the S&P 500’s entire gain. That kind of concentration makes investors nervous, and for good reason. While everyone piles into the same crowded names, smart investors are hunting quality where no one’s looking - and paying a fraction of the price. Check out the high-quality names we’ve flagged in our Top 9 Market-Beating Stocks. This is a curated list of our High Quality stocks that have generated a market-beating return of 244% over the last five years (as of June 30, 2025).
Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.
| Mar-10 | |
| Mar-10 | |
| Mar-09 | |
| Mar-06 | |
| Mar-06 | |
| Mar-06 | |
| Mar-05 | |
| Mar-05 | |
| Mar-05 | |
| Mar-05 | |
| Mar-05 | |
| Mar-04 | |
| Mar-03 | |
| Mar-02 | |
| Mar-02 |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about Finviz Elite